SAB Biotherapeutics Inc (SABS): Next-Year EPS Estimate 31.34%
As of 2026-06-11, SAB Biotherapeutics Inc (SABS) has a next-year EPS growth estimate of 31.34%.
On 2026-06-10, analyst consensus for SABS's next-year EPS growth shifted from 31.40% to 31.34% — a negative change of 0.06 percentage points. The revised estimate has been sustained across 2 subsequent trading sessions. Current-year growth is projected at -22.20%.
Current Snapshot
- Sector
- Healthcare
- Industry
- Biotechnology
- EPS growth next year
- 31.34%
- EPS growth this year
- -22.20%
- EPS next quarter (est)
- -$0.27
- Last price
- $3.38
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-06-11 | 31.34% | -22.20% | -$0.27 | $3.38 |
| 2026-06-10 | 31.34% | -22.20% | -$0.27 | $3.31 |
| 2026-06-09 | 31.40% | -21.57% | -$0.26 | $3.36 |
| 2026-06-08 | 31.40% | -21.57% | -$0.26 | $3.40 |
| 2026-06-07 | 31.40% | -21.57% | -$0.26 | $3.38 |
| 2026-06-04 | 31.40% | -21.57% | -$0.26 | $3.47 |
| 2026-06-03 | 31.40% | -21.57% | -$0.26 | $3.36 |
| 2026-06-02 | 31.40% | -21.57% | -$0.26 | $3.48 |
| 2026-06-01 | 31.40% | -21.57% | -$0.26 | $3.44 |
| 2026-05-31 | 31.40% | -21.57% | -$0.26 | $3.60 |
| 2026-05-28 | 31.40% | -21.57% | -$0.26 | $3.57 |
| 2026-05-27 | 31.40% | -21.57% | -$0.26 | $3.60 |
| 2026-05-26 | 31.40% | -21.57% | -$0.26 | $3.81 |
| 2026-05-25 | 31.40% | -21.57% | -$0.26 | $3.90 |
| 2026-05-24 | 31.40% | -21.57% | -$0.26 | $3.90 |
| 2026-05-21 | 34.54% | -18.12% | -$0.26 | $3.81 |
| 2026-05-20 | 34.54% | -18.12% | -$0.26 | $3.68 |
| 2026-05-19 | 34.52% | -26.08% | -$0.27 | $3.55 |
| 2026-05-18 | 34.52% | -26.08% | -$0.27 | $3.56 |
| 2026-05-17 | 34.52% | -26.08% | -$0.27 | $3.70 |
| 2026-05-14 | 39.79% | -24.56% | -$0.27 | $3.89 |
| 2026-05-13 | 39.79% | -24.56% | -$0.27 | $3.89 |
| 2026-05-12 | 46.09% | -4.36% | -$0.29 | $3.62 |
| 2026-05-11 | 37.62% | 8.12% | -$0.21 | $3.72 |
| 2026-05-10 | 37.62% | 8.12% | -$0.21 | $4.11 |
| 2026-05-07 | 37.62% | 8.12% | -$0.21 | $4.09 |
| 2026-05-06 | 37.62% | 8.12% | -$0.21 | $3.80 |
| 2026-05-05 | 37.62% | 8.12% | -$0.21 | $3.68 |
| 2026-05-04 | 37.62% | 8.12% | -$0.21 | $3.69 |
| 2026-05-03 | 37.62% | 8.12% | -$0.21 | $3.47 |
Screen Performance
Aggregate stats across all 1781 tickers our top-EPS-revision screen has flagged over the past 71 days.
- Median return since detection
- +3.8%
- % of tickers in the green
- 58%
- Median return on winners
- +18.5%
- Large revisions captured
- 788
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Frequently Asked Questions
What is SAB Biotherapeutics Inc's next-year EPS growth estimate?▾
As of 2026-06-11, SAB Biotherapeutics Inc (SABS) has a next-year EPS growth estimate of 31.34%, based on analyst consensus.
When was the latest EPS estimate revision for SABS?▾
The most recent revision occurred on 2026-06-10, when analysts adjusted the next-year EPS growth estimate from 31.40% to 31.34%.
What sector and industry does SAB Biotherapeutics Inc belong to?▾
SAB Biotherapeutics Inc operates in the Healthcare sector, specifically the Biotechnology industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. SABS appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. SAB Biotherapeutics Inc (SABS) appears here because it was detected by our daily top-EPS-revision-performer screen.
← All reports